Cancer Biomarkers: The Next Frontier in Precision Oncology and Early Detection
According to a new report published by Polaris Market Research, the global Cancer Biomarkers Market was valued at USD 26.48 billion in 2025 and is projected to reach USD 68.84 billion by 2034, expanding at a CAGR of 11.2% during the forecast period.
Market Overview:
The market has witnessed steady growth in recent years, driven primarily by the rising global cancer burden and the corresponding need for faster, more accurate diagnostic pathways. Continued advances in genomics and proteomics are broadening the pool of validated biomarkers available to clinicians, while growing adoption of liquid biopsy techniques is expanding non-invasive testing options beyond traditional tissue-based approaches. Demand for companion diagnostics is rising alongside the shift toward personalized medicine, as treatment decisions increasingly hinge on a patient's specific molecular profile. Market participants are prioritizing innovation in next-generation sequencing, capacity expansion, and strategic partnerships to strengthen their competitive positioning, and industry-wide market growth is expected to remain resilient through the forecast period as clinical validation standards mature and reimbursement pathways improve.
Key Market Insights:
The market was valued at USD 26.48 billion in 2025, with genetic biomarkers accounting for the largest share given their established role in detecting cancer-driving mutations and guiding personalized medicine decisions.
North America led the market in 2025 on the strength of its healthcare infrastructure and research investment, while Asia Pacific is on track to post the fastest regional market growth through 2034.
Proteomic biomarkers are the fastest-growing biomolecule segment, supported by expanding protein-expression profiling work and growing use of mass spectrometry and bioinformatics tools in biomarker discovery.
Market Dynamics:
Driver: The rising global incidence of cancer is the market's primary growth driver, increasing demand for biomarkers that enable early detection, prognosis, and personalized treatment planning.
Driver: Continued advancement in biomarker discovery technologies, including next-generation sequencing and high-throughput screening, is accelerating identification of new, more precise cancer biomarkers.
Restraint: The high cost of advanced profiling technologies, including NGS and multi-omics platforms, continues to limit adoption in cost-sensitive markets.
Restraint: Complex and time-intensive clinical and analytical validation pathways can delay commercialization, particularly for newer AI-supported liquid biopsy tests.
Opportunity: Integration of artificial intelligence into biomarker discovery and patient stratification is opening new avenues for faster, more precise oncology diagnostics.
Opportunity: Expanding liquid biopsy access in emerging healthcare markets, supported by rising cancer screening initiatives, presents a meaningful runway for market expansion.
Competitive Landscape:
The market is moderately consolidated, with key players focusing on capacity expansion, product innovation, and strategic partnerships to strengthen their market position. Leading companies continue to invest in research and development to introduce advanced, cost-efficient diagnostic solutions, while mergers, acquisitions, and cross-industry collaborations remain common strategies for broadening geographic reach and technology platforms, particularly in liquid biopsy and companion diagnostics.
Key Companies:
Abbott Laboratories
Agilent Technologies
Becton, Dickinson and Company
Bio-Rad Laboratories
Exact Sciences Corporation
Genomic Health, Inc. (part of Exact Sciences)
Guardant Health, Inc.
Hologic, Inc.
Illumina, Inc.
Myriad Genetics, Inc.
PerkinElmer, Inc.
Qiagen N.V.
Roche Diagnostics
Siemens Healthineers
Thermo Fisher Scientific
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
Recent Developments:
February 2025: BillionToOne announced that its comprehensive genomic profiling assay, Northstar Select, received Medicare coverage for eligible advanced solid tumors.
April 2025: Guardant Health announced a multi-year collaboration with Pfizer to support development and commercialization of Pfizer's oncology portfolio using the Guardant Infinity liquid biopsy platform.
April 2025: Natera announced its Signatera Genome assay became broadly available to physicians across the United States.
Market Segmentation
By Cancer Type Outlook (Revenue, USD Billion, 2021–2034)
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Others
By Biomarker Type Outlook (Revenue, USD Billion, 2021–2034)
PSA
HER-2
EGFR
KRAS
Others
By Biomolecule Outlook (Revenue, USD Billion, 2021–2034)
Genetic Biomarkers
Epigenetic Biomarkers
Metabolic Biomarkers
Proteomic Biomarkers
Others
By Profiling Technology Outlook (Revenue, USD Billion, 2021–2034)
Imaging Technology
OMICS
By Application Outlook (Revenue, USD Billion, 2021–2034)
Drug Discovery & Development
Diagnostics
Personalized Medicine
Others
Regional Insights:
North America: Held the largest market share in 2025, supported by advanced healthcare infrastructure, substantial cancer research investment, high testing penetration, and a strong base of pharmaceutical and biotechnology companies.
Asia Pacific: Expected to register the fastest regional market growth through 2034, driven by rising cancer incidence, expanding healthcare infrastructure, and growing government support in markets including China, India, and Japan.
Europe: A well-established market underpinned by strong healthcare systems and precision-oncology initiatives, with Germany, the UK, and France as leading contributors to regional research and adoption.
Latin America & Middle East and Africa: Emerging markets for cancer biomarkers, with growth supported by gradually improving healthcare access, rising cancer-screening awareness, and expanding diagnostic infrastructure investment.
Future Outlook:
The Cancer Biomarkers Market is expected to witness steady growth as precision oncology and personalized medicine gain wider adoption. Increasing cancer incidence is driving demand for biomarkers that support early detection, diagnosis, prognosis, and treatment monitoring. Advances in genomics, proteomics, liquid biopsy, and molecular diagnostics are expanding the range of clinically useful biomarkers.
Future growth will be supported by the integration of artificial intelligence and advanced data analytics into biomarker discovery and interpretation. Pharmaceutical companies are also increasingly using biomarkers in drug development and companion diagnostics. Greater clinical validation, regulatory support, and investment in cancer research are likely to create new opportunities across diagnostic and therapeutic applications.
Comments